Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis.

Ursula Maria VoglMarcello TucciTiziana AngustiAntonella ParenteRosario Francesco Di StefanoSusanna UrbanChiara PisanoAlessandro SamuellyAlessandro AudisioMarco AudisioElena ParlagrecoAntonio UngaroGiorgio Vittorio ScagliottiMassimo Di MaioConsuelo Buttigliero

Published in: Tumori (2022)

Discontinuation due to toxicity is associated with worse outcomes in mCRPC patients treated with Ra-223. To reduce the risk of developing toxicities that may compromise treatment efficacy, Ra-223 should be used early in mCRPC patients.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
rheumatoid arthritis
prognostic factors
peritoneal dialysis
type diabetes
oxidative stress
patient reported outcomes
adipose tissue
systemic lupus erythematosus
systemic sclerosis